RARP-ICG study

Phase 2

• Conditions: Prostate cancer; lymph node dissection; C61-6-20068229

• Registration Number: JPRN-jRCTs031180166
• Lead Sponsor: Fujimoto Hiroyuki

Brief Summary

We tried to clarify the lymph drainage system from prostate cancer when RARP was performed, but the trial was early cancelled because of the problem of equipment or surgeons. We could observe lymph drainage in all 5 patients, but could not reach a definite conclusion.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-04-13
• Study Start: 2019-03-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Male
• Target Recruitment: 5

Inclusion Criteria

1) Diagnosed as prostate cancer pathologically by prostate biopsy
2) Diagnosed as localized prostate cancer (T1-2N0M0) or locally advanced cancer (T3aN0M0) by DRE, CT, MRI
3) 20 years old and over, under 75
4) ECOG performance status score: 0 and 1
5) With or without measurable lesions
6) Provision of pretreatment: No history of hormone therapy, no history of surgery in the pelvis, no history of operation of the prostate
7) No restrictions on concomitant medications and combination therapy
8) With regard to complications, there is no restriction as long as it is judged that robot-assisted prostatectomy and extended lymph node dissection is possible by the attending physician
9) About patient participation The patient got consent in writing from the patient himself

Exclusion Criteria

Exclude those with allergic history in ICG

Study & Design

• Study Type: Interventional
• Study Design: Not specified